Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMIGAN 0.1 mg/mL versus 0.3 mg/mL 2-year safety study in glaucoma or ocular hypertension
2010-023917-68Phase 4Completed
- Sponsor
- Allergan
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bimatoprost in Glaucoma and ocular hypertension (2 arms), sponsored by Allergan. Started Feb 2011; status: completed.
02
Drugs
bimatoprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on 2010-023917-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023917-68.